https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Small cell lung cancer
MERU clinical trial : AbbVie ends Rova-T program in lung cancer

MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

Tecentriq wins FDA approval for extensive stage small cell lung cancer

Tecentriq FDA approval : Roche subsidiary Genetech has bagged a new approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab), this time in combination with chemotherapy as the first-line treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC). The chemotherapy to be used for the indication alongside Tecentriq is […]

Continue reading …
Pfizer lung cancer drug Lorbrena bags US FDA approval

Lorbrena FDA approval : US pharma giant Pfizer has bagged approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib) for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). Lorbrena FDA Approval The FDA approval of Lorbrena is for the ALK-positive NSCLC patient population whose condition has progressed on treatment […]

Continue reading …
BMS’ Opdivo flops in CheckMate -331 trial in small cell lung cancer

Bristol-Myers Squibb (BMS) cancer drug Opdivo (nivolumab) failed to meet the primary endpoint of the phase 3 CheckMate -331 trial in small cell lung cancer patients whose condition relapsed after platinum-based chemotherapy treatment. Opdivo could not significantly improve overall survival in the patients in comparison to current standard of care chemotherapy of topotecan or amrubicin […]

Continue reading …
PharmaMar lung cancer drug lurbinectedin gets FDA orphan drug designation

Spanish pharma company PharmaMar’s lurbinectedin has secured orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer. Lurbinectedin has been designed to inhibit the RNA polymerase II enzyme which is important for the transcription process that is over-activated in tumors with transcription addiction, according to PharmaMar. […]

Continue reading …